No Data
No Data
Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit
MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating
Q3 2024 MannKind Corp Earnings Call
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
loading...